Insulet Co. (NASDAQ:PODD) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Insulet Co. (NASDAQ:PODD) by 14.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 344,164 shares of the medical instruments supplier’s stock after selling 59,698 shares during the quarter. Fisher Asset Management LLC’s holdings in Insulet were worth $74,677,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Parkside Financial Bank & Trust lifted its holdings in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 123 shares in the last quarter. Allworth Financial LP increased its position in shares of Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after purchasing an additional 92 shares during the last quarter. Wolff Wiese Magana LLC increased its position in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 134 shares during the last quarter. BluePath Capital Management LLC bought a new stake in shares of Insulet in the 3rd quarter worth about $31,000. Finally, Lindbrook Capital LLC increased its position in shares of Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on PODD shares. Piper Sandler dropped their target price on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Barclays dropped their target price on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research report on Monday, February 26th. Stifel Nicolaus boosted their price objective on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research report on Monday, February 5th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Stock Up 0.6 %

PODD stock opened at $174.43 on Friday. Insulet Co. has a 12 month low of $125.82 and a 12 month high of $335.91. The firm has a market cap of $12.21 billion, a PE ratio of 59.94, a P/E/G ratio of 3.12 and a beta of 1.00. The firm has a 50 day simple moving average of $169.57 and a 200 day simple moving average of $180.68. The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. Equities research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the sale, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.47% of the stock is owned by insiders.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.